Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.
Wang
Sean Xiang
SX
Division of Hematology/Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA. wang2x2@ucmail.uc.edu
Byrnes
Abigail
A
Verma
Sadhna
S
Pancoast
John R
JR
Rixe
Olivier
O
D000368:Aged; D001557:Benzenesulfonates / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D054796:Drug Dosage Calculations; D016174:Hepacivirus / Q000472:pathogenicity*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008103:Liver Cirrhosis; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D012074:Remission Induction; D000077157:Sorafenib
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib